Endometrial Neoplasms
Conditions
Keywords
Drug Therapy
Brief summary
The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
Detailed description
The drugs being evaluated in this study are sapanisertib and MLN1117. Sapanisertib is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. This study will evaluate the efficacy and safety of each drug or drug combination. The study will enroll approximately 241 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of 4 treatment groups: * Paclitaxel 80 mg/m\^2 * Paclitaxel 80 mg/m\^2 + Sapanisertib 4 mg * Sapanisertib 30 mg * Sapanisertib 4 mg + MLN1117 200 mg Participants will receive either paclitaxel intravenous (IV) weekly, Paclitaxel IV along with sapanisertib orally, sapanisertib orally, or sapanisertib and MLN1117 orally. This is a multicenter, multinational trial. Participants will make multiple visits to the clinic, with an end of treatment visit (EOT) which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for PFS and overall survival (OS).
Interventions
DRUGPaclitaxel
Paclitaxel intravenous solution.
DRUGSapanisertib
Sapanisertib capsules.
DRUGMLN1117
MLN1117 capsules.
Sponsors
European Network of Translational Research in Ovarian Cancer - EUTROC
European Network of Individualized Treatment in Endometrial Cancer - ENITEC
Millennium Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologic or cytologic diagnosis of endometrial carcinoma (including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma). 2. Evidence that the endometrial cancer is advanced, recurrent, or persistent and has relapsed or is refractory to curative therapy or established treatments. 3. At least 1 prior platinum-based chemotherapeutic regimen, but not more than 2 prior chemotherapeutic regimens, for management of endometrial carcinoma. Prior treatment may include chemotherapy, chemotherapy/radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered in conjunction with primary radiation as a radio-sensitized therapy will be considered a systemic chemotherapy regimen. 4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded). Each lesion must be greater than or equal to (\>=) 10 millimeter (mm) in long axis when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam. Lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI. 5. Tumor accessible and participant consents to undergo fresh tumor biopsies. 6. Female participants 18 years or older. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 8. Female participants who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling \[example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc.\]) after the last dose of study drug, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[example, calendar, ovulation, symptothermal, postovulation methods\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.) 9. Clinical laboratory values as specified below within 4 weeks before the first dose of study drug: * Bone marrow reserve consistent with absolute neutrophil count (ANC) \>= 1500 per micro liter (/mcL); platelet count \>= 100,000/mcL; hemoglobin A1c (HbA1c) less than (\<) 6.5 percent (%). * Total bilirubin must be less than or equal to (\<=) 1.5 \* the upper limit of normal (ULN). * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be \<= 2.5 \* the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of metastatic disease in liver. * Creatinine clearance \>= 50 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) based either on Cockcroft-Gault estimate or based on a 12- or 24-hour urine collection. * Fasting serum glucose \< 130 milligram per deciliter (mg/dL) and fasting triglycerides \<= 300 mg/dL. 10. Ability to swallow oral medications, willingness to perform mucositis prophylaxis, and suitable venous access for the study-required blood sampling. 11. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
Exclusion criteria
1. Positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug. Women who are lactating and breastfeeding are not eligible. 2. Previous treatment with any weekly taxane regimen. 3. History of severe hypersensitivity reactions to paclitaxel or any of its excipients. 4. Previous treatment with phosphoinositide 3-kinase (PI3K), serine/threonine-specific protein kinase (AKT), dual PI3K/ mammalian (or mechanistic) target of rapamycin (mTOR) inhibitors, target of rapamycin complex 1/2 (TORC1/2) inhibitors or TORC1 inhibitors. 5. Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous \[IV\] or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (participants already receiving erythropoietin on a chronic basis for \>=4 weeks are eligible). 6. Participants who are taking proton pump inhibitors (PPIs) within 7 days of the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H2 receptor antagonists within 24 hours of the first dose of study drug. 7. A prothrombin time (PT) or activated partial thromboplastin time (aPTT) above the ULN or a history of a coagulopathy or bleeding disorder. 8. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection. 9. Sensory or motor neuropathy \>= Grade 2. 10. Central nervous system (CNS) metastasis, endometrial leiomyosarcoma, or endometrial stromal sarcoma. 11. Manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or for some other reason that may alter the absorption of sapanisertib or MLN1117. In addition, participants with enteric stomata are also excluded. 12. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active infection, or any other condition that could compromise participation of the participant in the study. 13. Known human immunodeficiency virus infection. 14. History of any of the following within the last 6 months before administration of the first dose of study drug: * Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures. * Ischemic cerebrovascular event, including transient ischemic attack and artery revascularization procedures. * Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia). * Placement of a pacemaker for control of rhythm. * New York Heart Association Class III or IV heart failure. * Pulmonary embolism. 15. Significant active cardiovascular or pulmonary disease before administration of the first dose of study drug, including: * Uncontrolled hypertension (that is, either systolic blood pressure \> 180 millimeter of mercury \[mm Hg\] or diastolic blood pressure \> 95 mm Hg). * Pulmonary hypertension. * Uncontrolled asthma or oxygen saturation \< 90% by arterial blood gas analysis or pulse oximetry on room air. * Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement. * Medically significant (symptomatic) bradycardia. * History of arrhythmia requiring an implantable cardiac defibrillator. * Baseline prolongation of the rate-corrected QT interval (QTc; example, repeated demonstration of QTc interval \> 480 millisecond \[ms\], or history of congenital long QT syndrome, or torsades de pointes). 16. Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. 17. Participants with endometrioid histology and histologically confirmed expression of estrogen receptors (ER) and/or progesterone receptors (PgR) who have not received prior endocrine therapy and for whom endocrine therapy is currently indicated.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Up to approximately 30 months | PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to approximately 54 months | OS is defined as the time in months from the date of randomization to the date of death. |
| Time to Tumor Progression (TTP) | Up to 30 months | TTP is defined as the time in months from the date of randomization to the date of first documentation of progression. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | From the first dose of study drug through 30 days after the last dose of study drug (Up to approximately 54 months) | An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. |
| Clinical Benefit Rate (CBR) | Up to 30 months | CBR is defined as the percentage of participants with CR or PR or SD (SD of any duration). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Clinical Benefit Rate (CBR) at Week 16 (CBR-16) | Week 16 | CBR-16 is defined as the percentage of participants who achieved CR or PR of any duration or have SD with a duration of at least 16 weeks. Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Overall Response Rate (ORR) | Up to 30 months | ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. |
Countries
Australia, Belgium, Canada, Germany, Italy, Netherlands, Norway, Spain, United Kingdom, United States
Participant flow
Recruitment details
Participants took part in the study at 60 investigative sites in Australia, Belgium, Germany, Italy, Netherlands, Norway, Spain, United Kingdom, Canada and the United States from 01 April 2016 to 30 October 2020.
Pre-assignment details
The female participants with a diagnosis of endometrial carcinoma were enrolled and randomized into 1:1:1:1 ratio to receive single agent paclitaxel, paclitaxel in combination with sapanisertib, single agent sapanisertib or sapanisertib in combination with MLN1117.
Participants by arm
| Arm | Count |
|---|---|
| Paclitaxel 80 mg/m^2 Paclitaxel 80 milligrams per square meter (mg/m\^2), IV, injection, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was 13.00 weeks). | 90 |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg Paclitaxel 80 mg/m\^2, IV, injection, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was 20.14 and 18.50 weeks). | 90 |
| Sapanisertib 30 mg Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was 6.14 weeks). | 41 |
| Sapanisertib 4 mg + MLN1117 200 mg Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was 7.43 weeks). | 20 |
| Total | 241 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Death | 58 | 59 | 30 | 16 |
| Overall Study | Lost to Follow-up | 4 | 3 | 0 | 1 |
| Overall Study | Reason not Specified | 2 | 1 | 0 | 0 |
| Overall Study | Site Terminated by Sponsor | 0 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 8 | 6 | 8 | 1 |
Baseline characteristics
| Characteristic | Paclitaxel 80 mg/m^2 | Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Sapanisertib 30 mg | Sapanisertib 4 mg + MLN1117 200 mg | Total |
|---|---|---|---|---|---|
| Age, Continuous | 63.7 years STANDARD_DEVIATION 7.14 | 64.4 years STANDARD_DEVIATION 7.63 | 64.0 years STANDARD_DEVIATION 6.99 | 62.0 years STANDARD_DEVIATION 10.2 | 63.9 years STANDARD_DEVIATION 7.57 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 5 Participants | 3 Participants | 4 Participants | 15 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 84 Participants | 80 Participants | 37 Participants | 15 Participants | 216 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants | 5 Participants | 1 Participants | 1 Participants | 10 Participants |
| Height | 160.60 cm STANDARD_DEVIATION 6.335 | 160.23 cm STANDARD_DEVIATION 5.798 | 159.01 cm STANDARD_DEVIATION 6.471 | 162.67 cm STANDARD_DEVIATION 5.854 | 160.36 cm STANDARD_DEVIATION 6.16 |
| Race/Ethnicity, Customized Asian | 6 Participants | 3 Participants | 1 Participants | 1 Participants | 11 Participants |
| Race/Ethnicity, Customized Black or African American | 3 Participants | 4 Participants | 0 Participants | 1 Participants | 8 Participants |
| Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Not Reported | 3 Participants | 3 Participants | 0 Participants | 0 Participants | 6 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 2 Participants | 2 Participants | 0 Participants | 4 Participants |
| Race/Ethnicity, Customized White | 77 Participants | 78 Participants | 37 Participants | 18 Participants | 210 Participants |
| Region of Enrollment Australia | 5 Participants | 6 Participants | 3 Participants | 2 Participants | 16 Participants |
| Region of Enrollment Belgium | 5 Participants | 10 Participants | 2 Participants | 3 Participants | 20 Participants |
| Region of Enrollment Canada | 15 Participants | 10 Participants | 2 Participants | 0 Participants | 27 Participants |
| Region of Enrollment Germany | 6 Participants | 4 Participants | 1 Participants | 0 Participants | 11 Participants |
| Region of Enrollment Italy | 14 Participants | 22 Participants | 9 Participants | 4 Participants | 49 Participants |
| Region of Enrollment Netherlands | 2 Participants | 3 Participants | 0 Participants | 0 Participants | 5 Participants |
| Region of Enrollment Norway | 3 Participants | 1 Participants | 1 Participants | 0 Participants | 5 Participants |
| Region of Enrollment Spain | 10 Participants | 7 Participants | 5 Participants | 6 Participants | 28 Participants |
| Region of Enrollment United Kingdom | 9 Participants | 4 Participants | 6 Participants | 2 Participants | 21 Participants |
| Region of Enrollment United States | 21 Participants | 23 Participants | 12 Participants | 3 Participants | 59 Participants |
| Sex: Female, Male Female | 90 Participants | 90 Participants | 41 Participants | 20 Participants | 241 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Weight | 73.29 kg STANDARD_DEVIATION 18.783 | 72.13 kg STANDARD_DEVIATION 18.433 | 75.35 kg STANDARD_DEVIATION 17.969 | 71.81 kg STANDARD_DEVIATION 18.613 | 73.11 kg STANDARD_DEVIATION 18.418 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 58 / 90 | 59 / 90 | 30 / 41 | 16 / 20 |
| other Total, other adverse events | 85 / 87 | 86 / 86 | 41 / 41 | 20 / 20 |
| serious Total, serious adverse events | 23 / 87 | 47 / 86 | 14 / 41 | 7 / 20 |
Outcome results
Primary
Progression Free Survival (PFS)
PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to approximately 30 months
Population: ITT population included all randomized participants. For a participant who had not progressed and was last known to be alive, PFS was censored at the last response assessment that is stable disease (SD) or better.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Paclitaxel 80 mg/m^2 | Progression Free Survival (PFS) | 3.7 months |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Progression Free Survival (PFS) | 5.6 months |
| Sapanisertib 30 mg | Progression Free Survival (PFS) | 2.1 months |
| Sapanisertib 4 mg + MLN1117 200 mg | Progression Free Survival (PFS) | 2.0 months |
p-value: =0.17895% CI: [0.58, 1.12]Stratified Log-rank Test
p-value: =0.09295% CI: [1.19, 2.86]Stratified Log-rank Test
p-value: =0.14795% CI: [1.47, 4.49]Stratified Log-rank Test
Secondary
Clinical Benefit Rate (CBR)
CBR is defined as the percentage of participants with CR or PR or SD (SD of any duration). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to 30 months
Population: Safety population included participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Paclitaxel 80 mg/m^2 | Clinical Benefit Rate (CBR) | 57.5 percentage of participants |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Clinical Benefit Rate (CBR) | 80.2 percentage of participants |
| Sapanisertib 30 mg | Clinical Benefit Rate (CBR) | 34.1 percentage of participants |
| Sapanisertib 4 mg + MLN1117 200 mg | Clinical Benefit Rate (CBR) | 35.0 percentage of participants |
95% CI: [1.53, 5.96]
95% CI: [0.18, 0.86]
95% CI: [0.15, 1.21]
Secondary
Clinical Benefit Rate (CBR) at Week 16 (CBR-16)
CBR-16 is defined as the percentage of participants who achieved CR or PR of any duration or have SD with a duration of at least 16 weeks. Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Week 16
Population: Safety population included participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Paclitaxel 80 mg/m^2 | Clinical Benefit Rate (CBR) at Week 16 (CBR-16) | 36.8 percentage of participants |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Clinical Benefit Rate (CBR) at Week 16 (CBR-16) | 51.2 percentage of participants |
| Sapanisertib 30 mg | Clinical Benefit Rate (CBR) at Week 16 (CBR-16) | 17.1 percentage of participants |
| Sapanisertib 4 mg + MLN1117 200 mg | Clinical Benefit Rate (CBR) at Week 16 (CBR-16) | 5.0 percentage of participants |
95% CI: [0.01, 0.67]
95% CI: [0.89, 7.67]
95% CI: [0.05, 0.51]
Secondary
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From the first dose of study drug through 30 days after the last dose of study drug (Up to approximately 54 months)
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Paclitaxel 80 mg/m^2 | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 87 Participants |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 86 Participants |
| Sapanisertib 30 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 41 Participants |
| Sapanisertib 4 mg + MLN1117 200 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 20 Participants |
Secondary
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
Time frame: Up to 30 months
Population: Safety population included participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Paclitaxel 80 mg/m^2 | Overall Response Rate (ORR) | 18.4 percentage of participants |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Overall Response Rate (ORR) | 24.4 percentage of participants |
| Sapanisertib 30 mg | Overall Response Rate (ORR) | 4.9 percentage of participants |
| Sapanisertib 4 mg + MLN1117 200 mg | Overall Response Rate (ORR) | 0 percentage of participants |
95% CI: [0.66, 2.9]
95% CI: [0.04, 1.14]
95% CI: [0, 0]
Secondary
Overall Survival (OS)
OS is defined as the time in months from the date of randomization to the date of death.
Time frame: Up to approximately 54 months
Population: ITT population included all randomized participants. Participants without documentation of death at the time of analysis were censored at the date last known to be alive.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Paclitaxel 80 mg/m^2 | Overall Survival (OS) | 12.7 months |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Overall Survival (OS) | 13.8 months |
| Sapanisertib 30 mg | Overall Survival (OS) | 12.5 months |
| Sapanisertib 4 mg + MLN1117 200 mg | Overall Survival (OS) | 11.1 months |
p-value: =0.96895% CI: [0.72, 1.5]Stratified Log-rank Test
p-value: =0.14595% CI: [0.95, 2.37]Stratified Log-rank Test
p-value: =0.24395% CI: [0.87, 2.73]Stratified Log-rank Test
Secondary
Time to Tumor Progression (TTP)
TTP is defined as the time in months from the date of randomization to the date of first documentation of progression. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to 30 months
Population: ITT population included all randomized participants. For a participant who has not progressed, TTP was censored at the last response assessment that is SD or better.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Paclitaxel 80 mg/m^2 | Time to Tumor Progression (TTP) | 3.7 months |
| Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg | Time to Tumor Progression (TTP) | 5.7 months |
| Sapanisertib 30 mg | Time to Tumor Progression (TTP) | 2.3 months |
| Sapanisertib 4 mg + MLN1117 200 mg | Time to Tumor Progression (TTP) | 2.2 months |
p-value: =0.1795% CI: [0.57, 1.11]Stratified Log-rank Test
p-value: =0.22495% CI: [1.04, 2.68]Stratified Log-rank Test
p-value: =0.24495% CI: [1.32, 3.96]Stratified Log-rank Test